

Sygnia Health Innovation Global Equity Fund Class A

Minimum Disclosure Document (MDD)

Class A


Global - Equity - General

31 December 2025

LOW	LOW MEDIUM	MEDIUM	MEDIUM HIGH	HIGH
LESS RISK/ RETURN		MORE RISK/ RETURN		
0 - 2 YEARS	2 YEARS+	3 YEARS+	5 YEARS+	7 YEARS+

Portfolio Manager	Wessel Brand, Mish-Al Bassadien
Regulation 28	Non-Compliant
Fund Launch Date	5 August 2020
Class Launch Date	5 August 2020
Fund Size	R 270 Million
Unit Price	121.10
Units in Issue	195,842,610

Cumulative Investment Performance



Performance Analysis

Periodic Performance	Fund	*BM	Difference
1 Month	-4.1%	-2.5%	-1.6%
3 Months	7.7%	-0.9%	8.6%
6 Months	5.9%	3.1%	2.7%
Year to Date	-0.8%	6.3%	-7.2%
1 Year	-0.8%	6.3%	-7.2%
**3 Years	3.3%	20.1%	-16.8%
**5 Years	6.6%	14.9%	-8.3%
Since Inception	4.3%	12.9%	-8.5%

*MSCI World Net Total Return Index

**Annualised performance figures

Historical Performance

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2020									-2.2%	-6.7%	2.0%	-2.2%	-9.0%
2021	5.2%	-3.7%	-0.1%	2.0%	-2.8%	7.3%	5.5%	3.3%	-0.8%	3.3%	3.6%	4.4%	30.0%
2022	-11.2%	-0.4%	-0.8%	3.2%	-1.4%	0.8%	4.4%	-3.0%	1.4%	8.7%	-4.6%	0.3%	-4.0%
2023	1.6%	2.2%	-2.4%	6.6%	4.2%	-1.9%	-4.0%	5.1%	-3.8%	-6.1%	5.6%	3.3%	10.0%
2024	4.1%	6.5%	-0.4%	-4.8%	1.4%	0.5%	2.3%	1.6%	-5.7%	-1.4%	-0.2%	-2.0%	1.2%
2025	4.7%	-1.3%	-3.2%	-0.5%	-6.6%	0.8%	1.1%	-0.2%	-2.6%	5.1%	6.8%	-4.1%	-0.8%

Risk Statistics

	Fund	BM
% Negative Months	46.7%	38.3%
Avg Negative Return	-2.9%	-2.8%
Maximum Drawdown	-16.3%	-18.4%
Standard Deviation	13.9%	14.2%
Downside Deviation	8.7%	6.7%
Highest Annual Return: Jan 2021 - Dec 2021	30.0%	32.4%
Lowest Annual Return: Sep 2024 - Aug 2025	-14.1%	15.3%

The risk statistics reflected above are calculated on a 60 month or since inception basis, depending on which period is shorter.

Investment Objective

Deliver strong long-term capital growth by investing in international equities

Income Distribution

Bi-annually (September and March)
No payment to date

Trustees

Standard Bank Trustees (021 441 4100)

Asset Allocation as at 31 December 2025

Sector	Percentage	Allocation
International Equities	100.0%	

Top 10 Holdings

Asset	Percentage
Eli Lilly Ord Shs	9.6%
SPDR MSCI World Health Care UCITS ETF	5.3%
Johnson & Johnson Ord Shs	5.2%
AbbVie Ord Shs	4.3%
Oxford Sciences Innovations PLC (GBP)	4.2%
UnitedHealth Group Ord Shs	3.1%
Roche Holding Par Shs	3.1%
Astrazeneca Ord Shs	2.9%
Merck & Co Ord Shs	2.8%
Novartis Ord Shs	2.8%

The above percentages include effective exposure in underlying unit trusts.

Fees

Initial Fee	0.00% **
Management Fee	0.70% **
Performance Fee*	0.00% **
Other costs	0.04% **
VAT	0.11%
Total Expense Ratio (TER)	0.85% (Dec 2025)
Transaction Costs (TC)	0.05% (Dec 2025)
Total Investment Charge (TIC)	0.90% (Dec 2025)

** Fees are exclusive of VAT

*Please note, the performance fee will increase to 20% of outperformance of the benchmark with a cap of 2.30%.

Sygnia Health Innovation Global Equity Fund

Fund commentary


Minimum disclosure document (MDD)

Class A

Global - Equity - General

4th Quarter 2025

RISK PROFILE



TIME HORIZON



Market performance

Global markets delivered impressive returns in 2025, with the dramatic 10% decline in the US dollar emerging as the defining force across asset classes. The greenback's weakest annual performance since 2017, driven largely by President Trump's punitive tariff regime, reshaped investment outcomes and created significant divergence between dollar-based and local currency returns.

The S&P 500 posted a 16% gain in dollar terms, supported by three additional Federal Reserve rate cuts totalling 75 basis points and by ongoing enthusiasm around artificial intelligence (AI) investments. While market leadership broadened modestly beyond mega-cap technology stocks, companies at the forefront of the AI revolution remained the primary drivers of performance.

Currency movements told a different story for domestic investors, however. The rand's 14% appreciation against the dollar significantly reduced US equity returns to just 2.2% in South African currency terms, highlighting the material impact of foreign exchange fluctuations on investment outcomes.

The real winners in 2025 were commodity-linked and emerging market (EM) assets. Gold and silver recorded their strongest annual gains since 1979, while copper surged by the most in a decade. This commodity rally propelled the FTSE/JSE Capped All Share Index to an exceptional 43% return, marking a standout year of domestic asset outperformance. The JSE All Bond Index gained 24.2%, the second consecutive year of strong double-digit returns for South African bonds.

EMs broadly benefitted from dollar weakness, with the MSCI Emerging Markets Index returning 17.3% in rand terms, outperforming the MSCI World Index by 11 percentage points.

The Federal Reserve cut rates by 25 basis points in December 2025, bringing the federal funds rate to 3.5–3.75%. While equity markets responded positively, reaching new all-time highs, Chair Jerome Powell's accompanying statement suggested limited additional easing ahead. The Fed's language describing policy as "appropriately positioned" mirrors the phrasing that preceded a nine-month pause in 2024. With inflation still running near 3% and Powell's term extending through May 2026, the central bank appears set to hold rates steady until at least mid-year. Markets are currently pricing in a potential cut in April or June, followed by another in September, while the Fed's own projections suggest just one cut for the entire year.

However, a significant wildcard is Powell's anticipated replacement by Kevin Hassett, who is viewed as more aligned with the Trump administration. Hassett has indicated he sees no tariff-related threat to the Fed's 2% inflation target, potentially opening the door to more aggressive rate cuts than currently anticipated.

This environment is expected to support a stronger dollar in the first half of 2026 before it weakens again and equity volatility increases as expectations adjust. Fixed income yields are likely to remain attractive at the front end of the curve, while longer-dated bonds may face pressure as tariff-driven inflation concerns filter through the market.

A further wildcard is Trump's proposed signature "Freedom Cheque" initiative, which represents approximately \$300 billion in annual direct payments to working-class households, equivalent to 1% of GDP.

Pending Congressional approval for a first-quarter 2026 rollout, this stimulus could push economic growth to 3.0–3.5%, well above the consensus estimate of 2.4%. With consumer spending being 70% of GDP, the program represents substantial demand stimulus. The fiscal implications are considerable. The US budget deficit could expand to 7.5% of GDP, and inflation may accelerate by 0.5–1 percentage point. With debt-to-GDP approaching 100%, concerns about fiscal sustainability are intensifying. Powell has already signalled that the Fed will not accommodate excessive fiscal stimulus, setting up potential policy tension later in the year.

US growth equities have reached extraordinary valuation levels by historical standards. The Shiller CAPE ratio, which adjusts for economic cycles, is at record highs and now exceeds levels seen in the dot-com bubble. Historical data suggest that after such valuation peaks, 10-year returns typically average just 0–3%. These elevated valuations increase the likelihood of heightened volatility and suggest the need for diversification and tempered return expectations.

While US markets trade at stretched valuations, EMs offer compelling alternatives. Trading at a CAPE ratio of just 13, EMs present the most attractive global valuations. Several factors support the case for EM exposure: many countries serve as critical links in the semiconductor supply chain benefitting from AI deployment; Chinese companies continue capturing global market share, particularly from European competitors; and commodity producers stand to benefit from AI data centre infrastructure buildouts and increased global defence spending.

European equities, trading at a CAPE ratio of 18, appear attractive on a relative basis but face structural challenges. Europe's productivity growth lags the US, Germany has continued to lose market share to China as infrastructure stimulus remains delayed, and France faces political gridlock. We generally prefer European bonds over equities given these headwinds.

We remain overweight equities through EM and South African equity exposure. We are underweight developed market bonds, particularly US Treasuries, offset by overweight positions in local currency EM bonds, which are expected to benefit from falling EM inflation and a weaker dollar environment.

Despite a constructive outlook, significant risks warrant monitoring. Geopolitical tensions are escalating between the US and Venezuela and between China and Japan, while prospects for a Russia-Ukraine peace deal remain uncertain. Tariff-driven inflation could force markets to reprice Federal Reserve rate cut expectations. Combined with elevated valuations and geopolitical uncertainty, we are bracing for heightened volatility throughout 2026.

The year ahead promises both opportunity and challenge as diverging growth dynamics, shifting monetary policy and stretched valuations create a complex environment for portfolio management. Geopolitics, fiscal stimulus and inflation expectations are likely to remain key themes as markets navigate this evolving landscape.

Fund performance

The healthcare sector rebounded strongly over the last quarter of 2025, and the Sygnia Health Innovation Global Equity Fund posted a strong performance of 7.7% in rand terms. The fund outperformed its benchmark, the MSCI World Net Total Return Index, which posted -0.9%.

In terms of sub-sectors, strong performances came from pharmaceuticals, biotechnology and life sciences tools & services. The fund saw positive contributions from its holdings in Eli Lilly and Co, Roche Holding AG and AstraZeneca PLC but was negatively affected by its positions in Abbott Laboratories, UnitedHealth Group Inc and Novo Nordisk A/S.

The fund maintains investments in leading companies driving cutting-edge advancements in healthcare technology, positioning it to capitalise on long-term innovation in the sector.

Disclaimer

Sygnia Collective Investments RF (Pty) Ltd is incorporated and registered under the law of South Africa and is registered under the Collective Investment Schemes Control Act, 2002 (Act No 45 of 2002). The company does not provide any guarantee with respect to the capital or return of the portfolio. Nothing in this document will be considered to state or imply that the collective investment scheme or portfolio is suitable for a particular type of investor.

Important information to consider before investing

Investment Objective & Strategy

The Sygnia Health Innovation Global Equity Fund is a Global-Equity-General portfolio which seeks to deliver long term capital growth by investing at least 80% of its assets outside South Africa and at all times invest in a minimum of 80% of equities. The portfolio will invest in financially sound equity securities, preference shares which generate capital growth, property shares and property related assets, fixed income securities and asset in liquid form, whether such securities, instrument or assets are listed or unlisted financial instruments (derivatives).

Balancing Risk and Reward

The portfolio represents Sygnia's best investment view on the optimal combination of securities required to achieve superior long-term returns at a reasonable level of risk at any time. The portfolio exploits the benefits of diversification and will change its exposure to different securities and sectors on an active basis, based on prevailing market conditions. The portfolio aims to achieve its investment objectives, whilst recognising that there will be significant short-term volatility and aims to protect capital over the medium to long term.

Collective Investment Schemes in Securities (unit trusts) are generally medium- to long-term investments. The value of units may go down as well as up and past performance is not necessarily an indicator of future performance. Unit trusts are traded at the ruling price and are allowed to engage in borrowing and scrip lending.

Annualised performance figures represent the geometric average return earned by the fund over the given time period. Unannualised performance represents the total return earned by the fund over the given time period, expressed as a percentage. Performance is calculated for the portfolio. Individual investor performance may differ as a result of initial fees, the actual investment date, the date of reinvestment and dividend withholding tax. Reinvestment of income is calculated on the actual amount distributed per participatory interest, using the ex-dividend date NAV price of the applicable class of the portfolio, irrespective of the actual reinvestment date.

Fees*

Sygnia charges an annual management fee comprised of applicable basic fees paid to underlying managers and Sygnia's annual service fee. Performance-based fees are calculated in terms of the supplemental deed fee for certain of our asset managers when they outperform the fund's stated benchmark. This performance fee will be paid by the fund to the underlying investment manager only when the fund's performance exceeds that of the benchmark. The performance fee, if any, shall be calculated and accrued daily, and payable monthly. The performance fee is based on a sharing rate of 20% and capped at 2.30% per annum, where the portfolio has been in existence for more than 365 days.

A schedule of fees and charges is available on request from Sygnia. Permissible deductions may include management fees, brokerage, STT, auditors fees, bank charges and trustee fees. Sygnia does not provide advice and therefore does not charge advice fees.

What is the Total Expense Ratio (TER) and Transaction Costs (TC)?

The total expense ratio (TER) is the annualised percentage of the fund's average assets under management that has been used to pay the fund's actual expenses over the past three years. Transaction costs are a necessary cost in administering the fund and impact fund returns. They should not be considered in isolation, as returns may be impacted by many other factors over time, including market returns, the type of financial product, the investment decisions of the investment manager and the TER. Since fund returns are quoted after the deduction of these expenses, the TER and transaction costs should not be deducted again from published returns. A higher TER does not necessarily imply a poor return, nor does a low TER imply a good return. The TER and transaction costs cannot be determined accurately because of the short lifespan of the specific class of the financial product. Calculations are based on actual data where possible and best estimates where actual data is not available.

Foreign Securities

The fund may also invest in foreign securities, which may be exposed to macroeconomic, settlement, political, tax, reporting or illiquidity risk factors that may be different to similar investments in South African markets. Fluctuations or movements in exchange rates may cause the value of underlying investments to go up or down.

Cumulative Investment Performance

Cumulative investment performance is for illustrative purposes only. The investment performance is calculated by taking all ongoing fees into account for the amount shown, with income reinvested on the reinvestment date.

How are unit prices calculated?

Unit prices are calculated on a net asset value basis, which is the total market value of all assets in the portfolio, including any income accruals and less any permissible deductions from the portfolio, divided by the number of units in issue. Forward pricing is used and fund valuations take place at approximately 15:00 each business day. Purchases and redemption requests must be received by the manager by 14:00 each business day to receive that day's price. The price shown is specific to this class. The fund size represents the portfolio size as a whole. Unit prices are updated by 10:00 every business day and are available on our website, www.sygnia.co.za.

Disclaimer

The fund may be closed to new investments at any time in order to be managed in accordance with its mandate. Sygnia Collective Investments RF (Pty) Ltd is incorporated and registered under the laws of South Africa and is registered under the Collective Investment Schemes Control Act, 2002 (Act No 45 of 2002). Sygnia Asset Management (Proprietary) Limited (FSP Registration No. 873), an authorised financial services provider, is the appointed investment manager of the fund. Sygnia Collective Investments RF (Pty) Ltd does not provide any guarantee with respect to the capital or return of the portfolio. Nothing in this minimum disclosure document will be considered to state or imply that the collective investment scheme or portfolio is suitable for a particular type of investor.

This document is for information purposes only and does not constitute or form any part of any offer to issue or sell, or any solicitation of any offer to subscribe for or purchase, any particular investment. Whilst reasonable care was taken in ensuring that the information contained in this document is accurate, Sygnia accepts no liability in respect of any damages and/or loss (whether direct or consequential) or expense of any nature which may be suffered as a result of reliance, directly or indirectly, on the information in this document.

Additional information such as fund prices, brochures, application forms and a schedule of fees and charges can be requested via admin@sfs.sygnia.co.za or 0860 794 642 (0860 SYGNIA).

CAPE TOWN: 7th Floor, The Foundry, Cardiff Street, Green Point, 8001 T +27 21 446 4940

JOHANNESBURG: Unit 40, 6th Floor Katherine & West Building, West Street, Sandton, 2196 T +27 10 595 0550

DURBAN: Office 2, 2nd Floor Ridgeview, 1 Nokwe Avenue, Ridgeside, Umhlanga Ridge, 4319 T +27 31 001 0650

www.sygnia.co.za | info@sygnia.co.za